|Mr. William J. Newell||CEO & Director||719.92k||N/A||1958|
|Dr. Trevor J. Hallam||Chief Scientific Officer||700.48k||N/A||1959|
|Dr. Arturo M. Molina||Chief Medical Officer||616.76k||N/A||1959|
|Dr. Shabbir T. Anik||Chief Technical Operations Officer||N/A||N/A||1953|
|Dr. James R. Swartz||Founder and Member of Scientific Advisory Board||N/A||N/A||N/A|
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Sutro Biopharma, Inc.’s ISS Governance QualityScore as of December 7, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 9.